IL-33, sST2, and CRP in Panic Disorder
ConditionPanic Disorder
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorElazığ Mental Health and Diseases Hospital
About this trial
Panic disorder (PD) is characterized by recurrent and unexpected panic attacks and is associated with significant functional impairment. Increasing evidence suggests involvement of immune-inflammatory mechanisms in PD. Elevated levels of inflammatory markers such as C-reactive protein (CRP) have been reported in PD; however, interleukin-33 (IL-33) and soluble suppressor tumorogenicity-2 (sST2), components of the IL-33/sST2 signaling axis, have not previously been investigated in PD. This cross-sectional case-control study aims to compare peripheral serum IL-33, sST2, and CRP levels between drug-naïve subjects diagnosed with PD and healthy controls (HCs). The findings may contribute to understanding the inflammatory mechanisms underlying PD.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Being between 18-65 years of age
Having a diagnosis of panic disorder (PD) according to DSM-5-TR and having presented to the hospital with panic attack symptoms of the disorder
Not having previously used any medication for psychiatric purposes (drug-naive)
Not having any additional active psychiatric disorders besides PD at the current presentation
Disqualifiers
Taking any medication or supplement in the last month
Incomplete completion of sociodemographic and scale data
Not volunteering to participate in the study
Being between 18-65 years of age
Trial population
The study population consisted of adult participants aged 18-65 years. The panic disorder (PD) group included consecutive subjects diagnosed with PD according to DSM-5-TR criteria who were admitted to the psychiatry clinic of Elazığ Mental Health and Diseases Hospital (Turkey). The healthy control (HC) group consisted of individuals from the general population who applied to the hospital medical board and had no current or past psychiatric or significant medical disorders. All participants provided informed consent prior to enrollment.
Trial design
Design model
Case-control
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
80 Participants
are grouped into 2 trial groupsGroup A: Panic Disorder (PD)
Group B: Healthy Control (HC)
Trial outcomes
Primary outcomes
1
Interleukin-33 (IL-33)
Interleukin-33 (IL-33) levels measured by ELISA (pg/ml).
Time frame
At hospital admission (baseline)2
Soluble Suppressor Tumorogenicity-2 (sST2)
Soluble Suppressor Tumorogenicity-2 (sST2) levels measured by ELISA (pg/ml)
Time frame
At hospital admission (baseline)3
C-Reactive Protein (CRP)
C-Reactive Protein (CRP) levels measured by ELISA (mg/dL)
Time frame
At hospital admission (baseline)Secondary outcomes
1
Aggregate Index of Systemic Inflammation (AISI)
Aggregate Index of Systemic Inflammation (AISI) is calculated using the following formula: (neutrophils × monocytes × platelets) / (lymphocytes). All the parameters mentioned here are complete blood count parameters.
Time frame
At hospital admission (baseline)2
DSM-5 Panic Disorder Severity Scale-Adult Form (PDS)
The DSM-5 Panic Disorder Severity Scale-Adult Form (PDS) is a 10-item self-assessment scale developed by the American Psychiatric Association (APA) that uses a five-point Likert scale (0=Never; 1=Sometimes; 2=Halfway through; 3=Most of the time; 4=Always). Participants consider how much their panic disorder has affected their personal lives in the past seven days when completing the scale. Scores obtained from the scale items indicate the severity of the panic disorder. The scale can be scored between 0 and 40, with higher scores indicating a more severe panic disorder. The mean total score is calculated by dividing the total raw score by the number of items on the scale.
Time frame
At hospital admission (baseline)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov